Investigating Keytruda Access Barriers in Guatemala Through Personal Stories
This investigative report by the International Consortium of Investigative Journalists (ICIJ) explores the human cost of limited access to Keytruda, the world's bestselling cancer drug. The narrative centers on Francisca Violeta Sam Colop, an Indigenous Maya K’iche’ educator in Guatemala who died in 2025 after struggling to obtain the medication for advanced melanoma. Despite a court order granting her access, the exorbitant cost—approximately $180,000 annually in Guatemala—proved insurmountable without insurer coverage. The article highlights how scarcity forces life-and-death decisions, contrasting legal records with the lived experiences of patients and their families. It reveals significant global price disparities for pembrolizumab, ranging from $29,000 in Indonesia to $208,000 in the United States. By visiting Sam Colop’s family in Quetzaltenango, journalists uncovered the emotional and financial toll of navigating opaque pharmaceutical pricing and inadequate health insurance systems. This story is part of the broader 'Cancer Calculus' investigation, illustrating how high drug prices impact vulnerable populations in Latin America and beyond, emphasizing the gap between legal victories and actual healthcare accessibility.
Wire timeline
Investigating Keytruda Access Barriers in Guatemala Through Personal Stories
This investigative report by the International Consortium of Investigative Journalists (ICIJ) explores the human cost of limited access to Keytruda, the world's bestselling cancer drug. The narrative centers on Francisca Violeta Sam Colop, an Indigenous Maya K’iche’ educator in Guatemala who died in 2025 after struggling to obtain the medication for advanced melanoma. Despite a court order granting her access, the exorbitant cost—approximately $180,000 annually in Guatemala—proved insurmountable without insurer coverage. The article highlights how scarcity forces life-and-death decisions, contrasting legal records with the lived experiences of patients and their families. It reveals significant global price disparities for pembrolizumab, ranging from $29,000 in Indonesia to $208,000 in the United States. By visiting Sam Colop’s family in Quetzaltenango, journalists uncovered the emotional and financial toll of navigating opaque pharmaceutical pricing and inadequate health insurance systems. This story is part of the broader 'Cancer Calculus' investigation, illustrating how high drug prices impact vulnerable populations in Latin America and beyond, emphasizing the gap between legal victories and actual healthcare accessibility.
ICIJ